Abstract
Melanoma vaccines are an exciting and increasingly attractive immunotherapeutic approach for malignant melanoma. Vaccines can be used for patients with high risk primary melanoma and regional disease, stages in the progression of melanoma for which there is presently no treatment. They are unique in their potential to prevent cancer in high risk individuals.
Multiple approaches are being followed to develop effective vaccines. It is too early to judge whether any of them effectively slow the progression of melanoma. However, it is clear that vaccines are safe to use, and that they can stimulate immune responses to melanoma in some patients. The specificity of these responses needs to be clarified, and multiple challenges remain to be overcome before effective vaccines to melanoma become available. We must first identify the antigens on melanoma that stimulate immune responses, define the immune effector mechanisms that are stimulated by vaccine immunization and identify those responsible for increasing resistance to tumor growth, devise appropriate ways of constructing vaccines that will induce such responses, and find adjuvants and/or immunodulators that will potentiate desirable immune responses.
Article PDF
Similar content being viewed by others
References
Bystryn, J-C: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens. J Immunol 120: 96–101, 1978
Holmes, EC, Kahan, BD, Morton, DL: Soluble tumor-specific transplantation antigens from methylcholanthrene-induced guinea pig sarcoma. Cancer 25: 373–379, 1970
Sanderson, CJ, Frost, P: The induction of tumor immunity in mice using glutaraldehyde treated tumor cells. Nature 248: 690–691, 1974
Dugan M, Oratz R, Harris MN, Roses DF, Speyer JL, Golomb F, Henn M, Bystryn J-C: Delayed tumor progression in melanoma patients with cellular immune response to melanoma vaccine. Clin Res 36: 495A, 1988
Cassel, WA, Murray, DR, Phillips, HS: A phase II study on the post-surgical management of stage II malignant melanoma with Newcastle disease virus oncolysate. Cancer 52: 856–860, 1983
Livingston, PO, Natoli, EJ, Calves, MJ, et al.: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84: 2911–2915, 1987
Wallack, MK, Bash, JA, Leftheriotis, E: Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch-Surg 122: 1460–1463, 1987
Seigler, HF, Cox, E, Mutzner, F: Specific active immunotherapy for melanoma. Ann Surg 100: 366–372, 1979
Berd, D, Mastrangelo, MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Investigation 6: 337–349, 1988
Mitchell, MS, Kan-Mitchell, J, Kempf, RA, Harel, W, Shau, H, Lind, S: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Research 48: 5883–5893, 1988
Hersey, P, Edwards, A, Coates, A, Shaw, H, McCarthy, W, Milton, G: Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother 25: 257–265, 1987
Morton, DL: Active immunotherapy against cancer: Present status. Seminars in Oncology 13 (2): 180–185, 1986
Bystryn, J-C: Vaccine immunotherapy of melanoma. In: Ferrone, S (ed) Human Melanoma: From Basic Research to Clinical Applications. Springer-Verlag, Berlin, 1990, pp 513–530
Kopf, AW: Host defense against malignant melanoma. Hosp Prac 6: 116, 1971
Mihm, MC, Fitzpatrick, TB, Lane-Brown, MM: Early detection of primary cutaneous malignant melanoma. NEJM 289: 689, 1973
Bystryn, J-C, Naughton, GK: The significance of vitiligo antibodies. J of Dermatol 12: 1–9, 1985
Bystryn, J-C, Rigel, D, Friedman, RJ, Kopf, A: The prognostic significance of hypopigmentation in malignant melanoma. Arch of Dermatol 123: 1053–1055, 1987
Lloyd, KO: An overview of melanoma-associated antigens. In: Veronesi, U, Cascinelli, N, Santinami, M (eds) Cutaneous Melanoma. Academic Press, New York, 1987, pp 387–393
Cochran, AJ, Hoon, DB: Immunological aspects of malignant melanoma. In: Veronesi, U, Cascinelli, N, Santinami, M (eds) Cutaneous Melanoma. Academic Press, New York, 1987, pp 47–61
Livingston, PO, Calves, MJ, Natoli, EJ: Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol 138: 1524–1529, 1987
Tucker, MA, Coleman, CN, Cox, RS: Risk of second cancers after treatment for Hodgkin's disease. NEJM 318: 76–81, 1988
Gross, L: The importance of dosage in the intradermal immunization against transplantable neoplasms. Cancer Res 3: 770–778, 1943
Revesz, L: Detection of antigenic differences in isologous host-tumor systems by pretreatment with heavily irradiated tumor cells. Cancer Res 20: 443–451. 1960
Avent, J, Vervaert, C, Seigler, HF: Non-specific and specific active immunotherapy in a B16 murine melanoma system. J Surg Oncol 12: 87–96, 1979
Johnston, D, Schachne, J, Bystryn, J-C: Identification of immunogenic B16 melanoma-associated antigens. J Biol Resp Mod 6: 108–120, 1987
Bystryn, J-C, Li, J, Henn, M, Oratz, R: Identification of immunogenic antigens in a polyvalent melanoma antigen vaccine. Proc Am Assoc Cancer Res 31: 280, 1990
Li J, Henn M, Oratz R, Bystryn J-C: The antibody response to immunization to a polyvalent melanoma antigen vaccine. J Invest Derm. In Press, 1990
Bystryn, J-C, Berstein, P, Liu, P: Immunophenotype of human melanoma cells in different metastases. Cancer Res 45: 5603–5607, 1985
Carey, TE, Takahashi, T, Resnick, LA: Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 73: 3278–3282, 1976
Shiku, H, Takahashi, T, Resnick, LA: Cell surface antigens of human malignant melanoma. J Exp Med 145: 784, 1977
Seibert, E, Sorg, C, Happle, R: Membrane associated antigens of human malignant melanoma. III. Specificity of human sera reacting with cultured melanoma cells. Int J Cancer 19: 172–178, 1977
Bystryn, J-C: Immunology and immunotherapy of human malignant melanoma. Dermatologic Clinics 3: 327–334, 1985
Pierce, CW, Karp, JA: Regulation immune response by suppressor T cells. Contemporary Topics in Immunobiology 5: 91, 1976
Oratz R, Harris MN, Roses DF, Henn M, Bystryn J-C: Effect of cyclophosphamide on the immunogenicity of a melanoma vaccine in patients with stage II malignant melanoma. In press, 1990.
Bystryn, J-C, Dugan, M, Oratz, R, Speyer, J, Harris, MN, Roses, DF: Vaccine immunotherapy of human malignant melanoma: Relationship between method of immunization, immunogenicity, and tumor progression. In: Fox, F (ed) Human Tumor Antigens and Specific Tumor Therapy. Alan R. Liss, Inc., New York, 1989, pp 307–315
Bystryn, J-C, Jacobsen, S, Harris, M: Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod 5: 211–224, 1986
Livingston, PO, Takeyama, H, Pollack, MS, Houghton, AN: Serological responses of melanoma patients to vaccines derived from allogenic cultured melanoma cells. Int J Cancer 31: 567–75, 1983
Livingston, PO, Albino, AP, Chung, TJ: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55: 713–720, 1985
Mahaley, MSJr, Gillespie, GY, Gillespie, RP, Watkins, PJ: Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 59: 208–16, 1983
Bystryn, J-C, Tedholm, CA, Heaney-Kieras, J: Release of surface macromolecules by human melanoma and normal cells. Cancer Res 41: 910–914, 1981
Bystryn, J-C: Shedding and degradation of cell-surface macromolecules and tumor-associated antigens by human melanoma. In: Reisfeld, RA, Ferrone, S, (eds) Melanoma Antigens and Antibodies. Plenum Press, New York, 1982, pp 37–52.
Oratz, R, Cockerall, C, Speyer, J, Harris, MN, Roses, DF, Bystryn, J-C: Induction of tumor-infiltrating lymphocytes in malignant melanoma metastasis by immunization to melanoma antigen vaccine. J Biol Res Mod 8: 355–358, 1989
Bystryn, J-C, Oratz, R, Harris, MH: Immunogenicity of a polyvalent melanoma antigen vaccine in man. Cancer 61: 165–170, 1988
Adler, A, Oratz, R, Lieber, L, Bystryn, JC: Effect of allogeneic melanoma vaccine or the in vitro cellular immune response. Proc Am Assoc Cancer Res 31: 252, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bystryn, JC. Tumor vaccines. Cancer Metast Rev 9, 81–91 (1990). https://doi.org/10.1007/BF00047590
Issue Date:
DOI: https://doi.org/10.1007/BF00047590